Novavax call volume above normal and directionally bullish
Bullish option flow detected in Novavax (NVAX) with 12,673 calls trading, 2x expected, and implied vol increasing almost 14 points to 90.76%.
InsideNoVa1d
FDA Delays Final Approval of Novavax COVID Vaccine
The delay dovetails with moves by Republican lawmakers in at least seven states to ban or limit mRNA vaccines. Some, ...
The Pharma Letter1d
$175 million milestone in jeopardy as FDA delays Novavax nod
US biotech Novavax (Nasdaq: NVAX) is still waiting on a decision from the Food and Drug Administration over full approval of its protein-based COVID-19 vaccine, despite the agency having set an April ...
FDA delays full approval of Novavax COVID-19 vaccine even though it was on track for clearance
The FDA has delayed granting full approval of Novavax's COVID-19 vaccine despite it being on track to be cleared until ...
Novavax Inc. stock underperforms Thursday when compared to competitors
Shares of Novavax Inc. NVAX slid 6.35% to $5.60 Thursday, on what proved to be an all-around dismal trading session for the ...
1NVAX, SNY : Despite Headwinds, Biotech Sell-Off Could Offer Buying Opportunity: Analyst
Biotech stocks face a tough 2025 with SMid-cap losses up to 40% YTD. BofA cites FDA changes, tariffs, and capital struggles but notes potential opportunities.
Explore more
Asianet Newsable on MSN2d
Novavax Vaccine Approval From FDA In Limbo, Says Report – But Retail Is Hopeful
Shares of Novavax were in the spotlight on Wednesday following reports that the company’s Covid-19 vaccine is unlikely to be ...
Novavax (NVAX) Stock Sinks As Market Gains: Here's Why
In the latest trading session, Novavax (NVAX) closed at $5.98, marking a -0.33% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.67%. At the same time, the ...
US FDA misses deadline for decision on Novavax's COVID-19 vaccine
The U.S. Food and Drug Administration has missed its deadline for making a decision on traditional approval for Novavax's ...
Novavax set to snap six days of losses as shares trade in green
Novavax (NVAX) stock rebounds 2.5% after six days of losses amid FDA approval delays for its COVID-19 vaccine.
Novavax believes BLA ‘ready for approval,’ waiting on action from FDA
Novavax (NVAX) issued the following update on the FDA BLA for the company’s COVID-19 vaccine: “Novavax can confirm that April 1, 2025, was the ...
FDA Delays Full Approval Decision On Novavax's COVID-19 Vaccine
Novavax's COVID-19 vaccine received FDA Emergency Use Authorization, but full approval faces delays as regulators request more data beyond the April 1 deadline.